Table 2 baseline characteristics
From: tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma
|  | NDMM (n = 20) | R/RMM (n = 22) |
|---|---|---|
Age | ||
Median—yr | 59 | 60 |
Range—yr | 38–75 | 44–76 |
Sex-no. (%) | ||
Male | 11 (55.0) | 14 (63.6) |
Female | 9 (45.0) | 8 (36.4) |
ECOG performance status-no. (%) | ||
0 | 7 (35.0) | 6 (27.3) |
1 | 11 (55.0) | 13 (59.1) |
2 | 2 (10.0) | 3 (13.6) |
R-ISS stage-no. (%) | ||
I | 3 (15.0) | 3 (13.6) |
II | 6 (30.0) | 7 (31.8) |
III | 11 (55.0) | 12 (54.5) |
Cytogenetics-no. (%) | ||
High risk | 6 (30.0) | 10 (45.5) |
 Del (17p) | 4 (20.0) | 7 (31.8) |
 t (14;20) | 2 (10.0) | 3 (13.6) |
 t (14;16) | 2 (10.0) | 2 (9.1) |
Standard risk | 12 (60.0) | 8 (36.3) |
Unknown/missing | 2 (10.0) | 4 (18.2) |
No. of previous regimens-no. (%) | ||
Median | – | 3 |
Range | – | 1–6 |
Previous therapy-no. (%) | ||
Bortezomib | – | 18 (81.8) |
Lenalidomide | – | 8 (36.4) |
ASCT | – | 4 (18.2) |